Horm Metab Res 2018; 50(05): 414-421
DOI: 10.1055/s-0043-123470
Endocrine Research
© Georg Thieme Verlag KG Stuttgart · New York

Similar Aquaporin9 and MAPK Expression Profiles in the Liver of Types 1 and 2 Diabetes Mellitus

Jiaojiao Hou*
1   Department of Anatomy, Chongqing Medical University, Chongqing, P. R. China
,
Yuan Li*
1   Department of Anatomy, Chongqing Medical University, Chongqing, P. R. China
,
Xüxia Ren*
1   Department of Anatomy, Chongqing Medical University, Chongqing, P. R. China
2   Department of Anatomy, Chongqing Medical and Health School, Chongqing, P. R. China
,
Fei Gao
3   Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, P. R. China
,
Yuqin Chen
1   Department of Anatomy, Chongqing Medical University, Chongqing, P. R. China
,
Yaoxing Yi
1   Department of Anatomy, Chongqing Medical University, Chongqing, P. R. China
,
Lili Kang
1   Department of Anatomy, Chongqing Medical University, Chongqing, P. R. China
,
Yürui Luo
1   Department of Anatomy, Chongqing Medical University, Chongqing, P. R. China
,
Mei Yang
1   Department of Anatomy, Chongqing Medical University, Chongqing, P. R. China
› Author Affiliations
Further Information

Publication History

received 18 October 2017

accepted 14 November 2017

Publication Date:
09 March 2018 (online)

Zoom Image

Abstract

Aquaporin-9 (AQP9) is an aquaglyceroporin that biophysically conducts water, glycerol, and other small solutes. AQP9 is expressed in hepatocytes on the sinusoidal surfaces of hepatocyte plates in the liver, where it is considered responsible for the glycerol uptake in gluconeogenesis. However, limited information is available on the expression and regulating mechanism of AQP9 in different hyperglycemia models. Thus, this study examined the expression patterns of AQP9 and mitogen-activated protein kinase (MAPK) in Types 1 and 2 diabetes mellitus (DM) to clarify the roles and regulating mechanism of AQP9 in gluconeogenesis. Compared with the control group, the AQP9 expression significantly increased in both Types 1 and 2 DM, and the increased expression was associated with the activation of phosphorylated JNK (p-JNK) and the inhibition of phosphorylated p38 (p-p38). By contrast, phosphorylated ERK remained stable in the liver with Type 1 or 2 DM. These effects could be reversed by insulin treatment. That is, insulin downregulated AQP9 by inhibiting p-JNK and activating p-p38. The upregulation of AQP9 could be involved in gluconeogenesis and co-regulated by the JNK and p38 MAPK pathway in both Types 1 and 2 DM.

* The first three authors contributed equally to this manuscript